Dr. David Cella from Northwestern University Feinberg School of Medicine on Patient-Reported Outcomes in a Clinical Setting
David Cella, PhD
Advertisement
Articles by David Cella, PhD
Dr. David Cella from Northwestern University Feinberg School of Medicine on the Value of Patient-Reported Outcomes
Dr. David Cella from Northwestern University Feinberg School of Medicine on Quality of Life Assessments' Cost Effectiveness
Dr. David Cella from Northwestern University Feinberg School of Medicine Explains the Increase in Quality of Life Assessments
Dr. David Cella from Northwestern University Feinberg School of Medicine on the Side Effect Focus of the Axitinib and Sorafenib Trial
Dr. Cella From Northwestern University Feinberg School of Medicine Discusses Axitinib and Sorafenib Axis Trial
Dr. Cella from Northwestern University Feinberg School of Medicine on Patient Assessment Reference Scores
Advertisement
Latest Updated Articles
Dr. Cella Discusses Axitinib and Sorafenib Axis TrialPublished: June 17th 2011 | Updated:
Dr. Cella on His Focus in the Axitinib and Sorafenib TrialPublished: June 21st 2011 | Updated:
Dr. Cella on the Increase in Quality of Life AssessmentsPublished: June 24th 2011 | Updated:
Dr. Cella on Patient Reported Data's Cost EffectivenessPublished: June 29th 2011 | Updated:
Dr. Cella on the Value of Patient-Reported OutcomesPublished: July 6th 2011 | Updated:
Dr. Cella on Patient-Reported Outcomes in a Clinical SettingPublished: July 12th 2011 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5